Dataset Information
Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports.
Ontology highlight
ABSTRACT: Rationale
Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice.Patient concerns
Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma.Diagnosis
They were diagnosed as refractory nasopharyngeal carcinoma.Interventions
A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients.Outcomes
Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein-Barr virus (EBV) DNA load.Lessons
Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.
SUBMITTER: Chen C
PROVIDER: S-EPMC6709293 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature
Publications
Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports.
Medicine 20190801 32
<h4>Rationale</h4>Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice.<h4>Patient concerns</h4>Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma.<h4>Diagnosis</h4>They were diagnosed as refractory nasopharyngeal carcinoma.<h4>Interventions</h4>A continuous infusion of Endostar, an antiangiogenic agent, com ...[more]